Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Point-of-Care Testing in an Era of Laboratory Consolidation

Executive Summary

As laboratories consolidate and form networks to reduce costs and improve efficiency, some embrace POC whole-heartedly, extolling its ability to save money. Others are eliminating whatever POC testing they currently offer, investing instead in infrastructure to improve efficiency and turn around times in their central laboratories.

You may also be interested in...



Status Check: Point-of-Care Testing in Hospitals

The in vitro diagnostics industry has looked for years to point-of-care testing in hospitals as a growth segment. The premise is sound--easy-to-use tests performed near the patient will yield faster results that enable physicians to make better on-the-spot treatment decisions. In reality, hospital demand is increasing, but not as fast as expected. A recent survey of one-third of US hospitals with 150 beds or more, by Enterprise Analysis Corp. seeks to understand POCT usage and demand trends.

Hospitals' Hang-Ups With Point-Of-Care Testing

The hospital market for point-of-care testing represents a conundrum for manufacturers. Demand for it is growing--but, with the exception of glucose monitoring, not as fast as proponents had expected. A recent survey of a third of US hospitals with 150 or more beds seeks to gather information about hospital point-of-care testing utilization and preferences.

A Sobered Abbott Buys i-Stat

Abbott Laboratories' acquisition of i-Stat for $392 million reflects the promise and limitations of point-of-care diagnostics. A decade ago, i-Stat was a giddy startup, on a mission to revolutionize laboratory medicine with a handheld diagnostics system that could run basic blood tests rapidly at the patients' bedside. While it has accomplished much, it is far from creating a revolution. Meanwhile, the timing of the deal comes as Abbott emerges from a four-year nightmare with the FDA in which the FDA forced it to pull many of its important immunoassay tests off the market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV000430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel